drugset / Trial / NCT03211572

The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers

NCT03211572

Phase 2 Unknown 82 enrolled Ottawa Hospital Research Institute
NaSingle-groupOpen-labelOther

Summary

Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers

Timeline

Start
2017-08
Primary completion
2018-08
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Subject Tamoxifen Small molecule 20 mg Oral

Indications